View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Curtis Yeung ... (+2)
  • Curtis Yeung
  • Greater China Research Team

Greater China Daily: Monday, February 16, 2026

Top Stories Economics | Money Supply M0 growth was weaker in Jan 26 due to Chinese New Year effects, while M2 growth rose to 9.0% yoy, the highest since 2023. New bank loans surged to Rmb4.71t and new TSF rose to Rmb7.22t, both above consensus forecasts. However, outstanding bank loan growth fell to a record-low 6.1% yoy, highlighting fragile underlying credit demand despite strong front-loaded lending. Sector Update | Healthcare The HSHCI rose 1.8%, outperforming the HSI, which declined by 3.8...

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

Merck & Co Inc: 1 director

A director at Merck & Co Inc sold 10,000 shares at 121.456USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

Novo Nordisk A/S: Sales and EBITDA correction will widen in 2026, a cr...

Weaker 2026 outlook will pressure cash flow and slightly increase leverage

Boston Scientific Corp: 1 director

A director at Boston Scientific Corp sold after exercising options/sold 160,901 shares at 93.495USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...

Boston Scientific Corporation: Update to credit analysis following Pen...

Our credit view of this issuer reflects its leading market positions and strong operating performance tempered by an ongoing appetite for acquisitions

Boston Scientific Corporation: Update to credit analysis following Pen...

Our credit view of this issuer reflects its leading market positions and strong operating performance tempered by an ongoing appetite for acquisitions

Boston Scientific Corporation: Update to credit analysis following Pen...

Our credit view of this issuer reflects its leading market positions and strong operating performance tempered by an ongoing appetite for acquisitions

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Upgrading Financials and Consumer Discretionary We maintain our near-term bullish outlook on the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM), which has remained in place since 4/22/25, aside from one week (11/19/25-11/25/25) when we flipped to neutral. We will stay near-term bullish as long as crucial support levels of 6480-6520 on SPX, $580-$583 on QQQ, and $245 on IWM continue to hold. Market dynamics have mildly deteriorated, but it is nothing abnormal considering the broad marke...

Eli Lilly and Company: Update to credit analysis following outlook cha...

Our credit view of this issuer reflects its growth portfolio in oncology, neuroscience and immunology, offset by its revenue concentration in diabetes / metabolic conditions.

Edwards Lifesciences Corp: 3 directors

Three Directors at Edwards Lifesciences Corp sold/sold after exercising options/gave away 22,120 shares at between 0.000USD and 84.029USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretion...

Moody's Ratings affirms Eli Lilly's Aa3 rating; revises outlook to pos...

Moody's Ratings (Moody's) affirmed the ratings of Eli Lilly and Company ("Lilly") including the Aa3 senior unsecured notes ratings and long-term issuer rating, the (P)Aa3 senior unsecured shelf and medium term note program ratings, and the Prime-1 short-term commercial paper rating. At the same time...

Novo Nordisk A/S - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

New Lockout Rally Underway? We had a near-term bullish outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) from 4/22/25 to 11/19/25. After being near-term neutral for a week, we flipped back to bullish in our 11/25/25 Compass last week, all while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). We will stay near-term bullish as long as crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ continue to hold. We will maintain our bullish intermediate-term view...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

Novo Nordisk A/S: Key facts and statistics - LTM June 2025

A summary company profile, detailing Novo Nordisk A/S’s business operations and financial highlights.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch